US drugmaker Lilly’s Q4 2024 net income increases to $4.4bn
The pharmaceutical company reported a total revenue of $13.53bn for Q4 2024, a 45% rise compared to $9.35bn for the same quarter in 2023, and an 18% increase compared to...
Relmada acquires Tourette syndrome candidate Sepranolone from Asarina Pharma
Dr. Reddy’s enters into collaboration with Henlius for commercialisation of daratumumab
GSK’s Q4 2024 net income increases by 18% to £414m
Arbor Biotechnologies Announces FDA Orphan Drug and Rare Pediatric Disease Designations Granted to ABO-101
EC approves Henlius’ serplulimab for ES-SCLC treatment
Analysis
View More
Risks
View MoreSocietal polarisation and its impact on the pharmaceutical industry
Societal polarisation presents significant challenges for the pharmaceutical industry, affecting regulatory landscapes, public trust, innovation, and market dynamics
Effects of interstate armed conflicts on the pharmaceutical industry
Unveiling the impact of misinformation and disinformation in the pharmaceutical industry
The ripple effects of inflation on the pharmaceutical industry
Extreme weather events: The implications for the pharmaceutical industry